Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to -$17.6 million.

  • Vistagen Therapeutics' Cash from Operations fell 7150.78% to -$17.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$60.3 million, marking a year-over-year decrease of 5453.87%. This contributed to the annual value of -$42.1 million for FY2025, which is 6309.61% down from last year.
  • Per Vistagen Therapeutics' latest filing, its Cash from Operations stood at -$17.6 million for Q4 2025, which was down 7150.78% from -$13.8 million recorded in Q3 2025.
  • Over the past 5 years, Vistagen Therapeutics' Cash from Operations peaked at -$4.7 million during Q4 2023, and registered a low of -$18.8 million during Q2 2025.
  • Its 5-year average for Cash from Operations is -$11.2 million, with a median of -$10.6 million in 2024.
  • Per our database at Business Quant, Vistagen Therapeutics' Cash from Operations plummeted by 87739.88% in 2021 and then surged by 6211.94% in 2023.
  • Vistagen Therapeutics' Cash from Operations (Quarter) stood at -$12.0 million in 2021, then rose by 17.54% to -$9.9 million in 2022, then surged by 52.21% to -$4.7 million in 2023, then plummeted by 116.56% to -$10.3 million in 2024, then tumbled by 71.51% to -$17.6 million in 2025.
  • Its Cash from Operations stands at -$17.6 million for Q4 2025, versus -$13.8 million for Q3 2025 and -$18.8 million for Q2 2025.